echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > China successfully develops inactivated vaccine for highly pathogenic pig blue ear disease

    China successfully develops inactivated vaccine for highly pathogenic pig blue ear disease

    • Last Update: 2020-07-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    reporter 7 from the Ministry of Agriculture was informed that, after a large number of trials and large-scale clinical applications confirmed that China's self-developed highly pathogenic pig blue ear disease inactivated vaccine safety,effectiveness in line with the requirements of procedures, the current national highly pathogenic pig blue ear disease epidemic has been effectively controlledAccording to the latest statistics of the Ministry of Agriculture, from October 1 to2
    5, the number of highly pathogenic pig blue ear disease in china2
    9, with 3,608 cases ofand 710deadCompared with September,,87 per cent and 91 per cent, respectively, were decreasedIn the first half of this year, the outbreak of highly pathogenic pig blue ear disease continued to circulate, and in the second half of the year, with the supply of highly pathogenic blue ear disease vaccine gradually increased, the outbreak of pig disease was effectively curbedDuring the period from July to August, the incidence of outbreaks of live pigs decreased significantly compared to June and the same period last yearIn the summer of 2006
    , the southern provinces of China experienced a "high fever" outbreak of pigs After comprehensive analysis by experts and many reviews, it was determined that the virus was the primary cause of "high fever" in pigs, and was named "highly pathogenic pig blue ear disease" After determining the pathogen of highly pathogenic pig blue ear disease, the Ministry of Agriculture organized the of the China Animal Disease Prevention and Control Center, the the Chinese Veterinary Drug Inspection Institute and other relevant unit researchers to make every effort to speed up the development of vaccines So far, , the Ministry of Agriculture has allocated nearly 1 billion milliliters of vaccine to highly pathogenic pig blue ear disease At present, all enterprises produced vaccines before the market have carried out a safety test , security pass rate of 100%, in practice, , except for individual pig farms with minor adverse reactions , the vast majority of adverse reactions According to the Ministry of Agriculture's survey of the effectiveness of vaccine use in 69 cities in 17 provinces
    , from 11 enterprises produced 2 4 batches of vaccine use effect, pig vaccination after no major adverse reactions The application of the highly pathogenic pig blue ear disease vaccine has effectively curbed the occurrence and epidemic of the epidemic According to statistics, 2
    006, China due to "high fever" of 3.798 million pigs, 992,000 deaths From January 1 to October 25 this year, only 310,000 pigs with highly pathogenic pig blue ear disease and 81,000 deaths were contained In addition to strengthening comprehensive prevention and control measures, the timely application of vaccines is a key factor in the decline of the epidemic According to the Ministry of Agriculture's follow-up survey on vaccine use, there were no new outbreaks of highly pathogenic pig blue ear disease in health pig farms after being immunized with qualified vaccines Ministry of Agriculture officials said that the laboratory trial and testing and research confirmed that the vaccine's protection rate of intensity attacks is more than 80% Due to the emergency epidemic prevention period can not be in accordance with the procedures to complete the effectiveness of the vaccine before the distribution, but retrospective efficacy testing showed that the rate of detection of the virus protection rate accounted for 88.2% According to the supply and demand of vaccines, the Ministry of Agriculture has decided to stop the emergency issuance procedure for vaccines from October 25, requiring that the vaccine safety test and effectiveness test must meet the standards, and that vaccines with a vaccine protection rate of less than 80% are prohibited from leaving the factory
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.